T0	KEYPHRASE_NOTYPES 17 33	orthotopic model
T1	KEYPHRASE_NOTYPES 74 95	NB cell implant; mice
T2	KEYPHRASE_NOTYPES 105 128	pseudo-metastatic model
T3	KEYPHRASE_NOTYPES 167 184	NB cell injection.
T4	KEYPHRASE_NOTYPES 192 213	therapeutic schedules
T5	KEYPHRASE_NOTYPES 290 342	established and pseudo-metastatic preclinical models
T6	KEYPHRASE_NOTYPES 391 402	treated i.v.
T7	KEYPHRASE_NOTYPES 585 601	group of control
T8	KEYPHRASE_NOTYPES 616 637	HEPES-buffered saline.
T9	KEYPHRASE_NOTYPES 690 720	determining treatment efficacy.
T10	KEYPHRASE_NOTYPES 838 852	X-ray analyses.
T11	KEYPHRASE_NOTYPES 876 893	GI-LI-N cell line
T12	KEYPHRASE_NOTYPES 940 1046	firefly luciferase gene, as previously reported [17]; luciferase activity of retrovirally-transduced cells
T13	KEYPHRASE_NOTYPES 1073 1076	BLI
T14	KEYPHRASE_NOTYPES 1219 1233	X-ray analysis
